N/A N=68 Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
HIV · Hepatitis C, Chronic
Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Malignant Peripheral Nerve Sheath Tumors (MPNST) · Sarcoma
Primary: Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. — 0; 1 DLTs
Phase 2 N=50 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Acute Myelogenous Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1…
N/A N=52 Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
Type2 Diabetes
Primary: Program Enrollment Rate (%) — 14 Percentage of participants
Phase 3 N=750 Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Open-angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 24.69; 24.66; 24.75; 23.33 mmHg — p=<0.0001
Phase 3 N=553 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Ovarian Neoplasms · Platinum Sensitive Ovarian Cancer
Primary: Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) — 21; 5.5 months — p=<0.0001
Phase 4 N=30 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
Diabetic Macular Edema
Primary: Reduction in Macular Edema — 15; 8; 4 Participants
Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Phase 1 N=4 Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 5; 3; 1; 1 Participants
N/A N=123 Cervical Foley Plus Vaginal Misoprostol for Labor Induction
Induction of Labor
Primary: Time From Start of Labor Induction to Vaginal Delivery — 15.3; 18.3 hour — p=0.03
N/A N=20 Feasibility of Home-based Virtual Reality Rehabilitation for the Upper Extremity in Subacute and Chronic Stroke
Stroke
Primary: Device Use — 27 days
Phase 2 N=157 A Phase2 of A-101 Topical Solution in Subjects With Common Warts
Common Wart
Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)
Phase 2 N=170 Broccoli Sprout Dose Response: Bioavailability and Effects of Air Pollutants
Environmental Carcinogenesis
Primary: Sulforaphane Bioavailability Measured in Sequential 12-Hour Urine Samples — 24.8; 11.0; 4.3 micromoles/24 hours — p=<0.001
Phase 2 N=402 Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Fracture Healing
Primary: Time to Radiographic Healing — 16.4; 18.6; 18.3; 18.2 weeks — p=0.3598
Phase 3 N=218 BAX 855 Continuation
Hemophilia A
Primary: Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII) — 0; 0; 0; 0 Participants